It’s relentless. All the progress over the past two years and this seems to be heading straight back towards the price this was at prior to FDA approval. The post-approval slump seems to be such a recurring theme now for these pharma/bio companies that the shorters just pile in on them and take them to irrationally low levels. Doesn’t help either that the broader biotech and pharma sector continues to remain an underperforming sector (though there are signs that a rotation is beginning to occur with money now flowing back into these underperforming sectors, seeking out undervalued opportunities in an overvalued market)
Ann: Trofinetide marketing application submitted in Europe, page-14
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$12.54 |
Change
0.100(0.80%) |
Mkt cap ! $1.559B | |||
| Open | High | Low | Value | Volume |
| $12.44 | $12.73 | $12.13 | $11.07M | 885.6K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1215 | $12.52 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $12.54 | 804 | 1 |
View Market Depth
| Last trade - 16.10pm 20/06/2025 (20 minute delay) ? |
| NEU (ASX) Chart |